Interim results from the NADIM ADJUVANT Phase III clinical trial, led by the Spanish Lung Cancer Group (GECP), demonstrate that adjuvant chemo-immunotherapy significantly reduces disease recurrence risk in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC). These findings provide pivotal evidence supporting the use of combined chemotherapy and immunotherapy in early-stage NSCLC treatment settings, potentially influencing clinical guidelines and patient outcomes.